ARCTURUS THERAPEUTICS HOLDINGS INC. Form 8-K (May 7, 2020)

Summary

Current report on Form 8-K of Arcturus Therapeutics Holdings Inc., date of report May 7, 2020, filed under Item 2.02, Results of Operations and Financial Conditions. It states that on May 7, 2020 the company issued a press release, furnished as Exhibit 99.1, announcing financial results for the quarter ended March 31, 2020 and providing a corporate update. The report includes a cautionary note on forward-looking statements covering the COVID-19 vaccine effort and the partnership with Catalent, and says that no assurances can be given that a vaccine can or will ever be developed or approved using the company's technology. The signature block shows /s/ Joseph E. Payne, dated May 7, 2020.

Summary drafted by a model from the document's text below and checked by script against that text before publication. It is a navigation aid, not a reading of what the document proves. Where AI is used

Full text

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 8-K

CURRENT REPORT

Pursuant to Section 13 or 15(d)

of the Securities Exchange Act of 1934

Date of Report (Date of earliest event
reported): May 7, 2020

ARCTURUS THERAPEUTICS HOLDINGS INC.

(Exact name of registrant as specified
in its charter)

Delaware | 001-38942 | 32-0595345
(State or other jurisdiction of incorporation) | (Commission File Number) | (I.R.S. Employer Identification No.)

10628 Science Center Drive, Suite 250

San Diego, California 92121

(Address of principal executive offices)

Registrant’s telephone number,
including area code: (858) 900-2660

(Former name or former address, if changed
since last report)

Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

☐ | Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ | Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ | Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ | Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class | Trading Symbol(s) | Name of each exchange on which registered
Common stock, par value $0.001 per share | ARCT | The NASDAQ Stock Market LLC

Indicate by check mark whether the registrant is an emerging
growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities
Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company ☐

If an emerging growth company, indicate by check mark if the
registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards
provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02. Results of Operations and Financial Conditions

On May 7, 2020, Arcturus Therapeutics Holdings Inc. (the “Company”
or “Arcturus”) issued a press release, a copy of which is furnished herewith as Exhibit 99.1, announcing the Company’s
financial results for the quarter ended March 31, 2020 and providing a corporate update (the “Press Release”).

The information contained in Item 2.02 of this Current Report
on Form 8-K, including the Press Release, shall not be deemed “filed” for the purposes of Section 18 of the Securities
Exchange Act of 1934, as amended, or otherwise subject to the liability of that section or Sections 11 and 12(a)(2) of the Securities
Act of 1933, as amended. In addition, this information shall not be deemed incorporated by reference into any of the Company’s
filings with the Securities and Exchange Commission, except as shall be expressly set forth by specific reference in any such filing.

Cautionary Note Regarding Forward-Looking Statements

Certain statements in this communication and the Press Release
are forward-looking statements” that involve substantial risks and uncertainties for purposes of the safe harbor provided
by the Private Securities Litigation Reform Act of 1995.

The Press Release contains forward-looking statements that involve substantial risks and uncertainties for purposes of the
safe harbor provided by the Private Securities Litigation Reform Act of 1995. Any statements, other than statements of historical
fact included in the Press Release, including those regarding the Company’s expected performance, the Company’s
development of any specific novel mRNA therapeutics, the Company’s efforts to develop a vaccine against COVID-19 based
on the Company’s mRNA therapeutics, the forecasted safety, efficacy or reliability of a vaccine against COVID-19,were
one to be successfully developed based on the Company’s mRNA therapeutics, the timing and availability of a vaccine
against COVID-19 were one to be successfully developed based on the Company’s mRNA therapeutics, the potential initiation
of human trials of a vaccine against COVID-19 based on the Company’s mRNA therapeutics, the timing of initiation of
human trials of a vaccine against COVID-19 based on the Company’s mRNA therapeutics, the ability of any product to receive
regulatory approval in Singapore and whether or not any other countries will accept the trials conducted in that jurisdiction,
the potential market impact of a vaccine against COVID-19 based on the Company’s mRNA therapeutics, the potential manufacturing
capabilities of the Company’s partnership with Catalent, the timing of technology transfer related to the Company’s
partnership with Catalent, the manufacture of GMP batches of a vaccine against COVID-19, were one to be successfully developed
based on the Company’s mRNA therapeutics, any expected benefit from the Company’s partnership with Catalent and
timing of any benefits related thereto, our current cash position and expected cash burn and the impact of general business
and economic conditions are forward-looking statements. Arcturus may not actually achieve the plans, carry out the intentions
or meet the expectations or projections disclosed in any forward-looking statements such as the foregoing and you should not
place undue reliance on such forward-looking statements. Such statements are based on management’s current expectations
and involve risks and uncertainties, including those discussed under the heading "Risk Factors" in Arcturus’ Annual
Report on Form 10-K for the fiscal year ended December 31, 2019, filed with the SEC on March 16, 2020 and in subsequent filings
with, or submissions to, the SEC. No assurances can be given that any results reported in pre-clinical studies can be replicated
in further studies or in human beings, or that a vaccine can or will ever be developed or approved using the Company’s
technology.

The statements made in this Current Report on Form 8-K and the
Press Release speak only as of the date stated herein, and subsequent events and developments may cause the Company’s expectations
and beliefs to change. While the Company may elect to update these forward-looking statements publicly at some point in the future,
the Company specifically disclaims any obligation to do so, whether as a result of new information, future events or otherwise,
except as required by law. These forward-looking statements should not be relied upon as representing the Company’s views
as of any date after the date stated herein.

Item 9.01. Financial Statements and Exhibits

(d) Exhibits.

Exhibit No. | Description of Exhibit
99.1 | Press Release of Arcturus Therapeutics Holdings dated May 7, 2020

SIGNATURES

Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

Arcturus Therapeutics Holdings Inc.
Date: May 7, 2020
By: | /s/ Joseph E. Payne
Name: | Joseph E. Payne

File and source

File

SEC_ARCT_8-K_filed2020-05-07_0001193805-20-000565.htm

Size

19,652 bytes

SHA-256

ce397390a0b55e66eacfcf4643a74c4d769a8feda985a0907bdf724b1ef20309

Our copy

SEC_ARCT_8-K_filed2020-05-07_0001193805-20-000565.htm

Original

www.sec.gov